Selective activation of the prostanoid EP3 receptor reduces myocardial infarct size in rodents

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 9, 1999, Pages 2141-2147

  Zacharowski, Kai ^a   Olbrich, Antje ^a   Piper, Julie ^a   Hafner, Gerd ^b   Kondo, Kigen ^c   Thiemermann, Christoph ^a,d  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c ONO PHARMACEUTICAL CO   (Japan)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ATP sensitive potassium channels; E type prostaglandin receptor agonist; Myocardial injury; Protein kinase C; Rodents

Indexed keywords

5 HYDROXYDECANOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ADENOSINE TRIPHOSPHATE; CHELERYTHRINE; CYCLIC AMP; DRUG VEHICLE; FORSKOLIN; ILOPROST; ONO AE 248; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTANOID; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; SULPROSTONE; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT;

EID: 0032830256     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.9.2141     Document Type: Article

References (26)

1. Coleman RA, Kennedy I, Humphrey PPA, Brunce K, Lumley P. In: Hansch C, Samnes PG, Taylor JB, Emmet JC, eds. Comprehensive Medicinal Chemistry. Oxford, England: Pergamon Press; 1990;643-651.
2. Namba T, Sugimoto Y, Negishi M, Irie A, Ushikubi F, Kakizuka A, Ito S, Ichikawa A, Narumiya S. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity, [see comments]. Nature. 1993;365:166-170.
3. Sugimoto Y, Negishi M, Hayashi Y, Namba T, Honda A, Watabe A, Hirata M, Narumiya S, Ichikawa A. Two isoforms of the EP3 receptor with different carboxyl-terminal domains: identical ligand binding properties and different coupling properties with Gi proteins. J Biol Chem. 1993;268:2712-2718.
4. Kotani M, Tanaka I, Ogawa Y, Usui T, Mori K, Ichikawa A, Narumiya S, Yoshimi T, Nakao K. Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol. 1995;48:869-879.
5. Irie A, Sugimoto Y, Namba T, Harazono A, Honda A, Watabe A, Negishi M, Narumiya S, Ichikawa A. Third isoform of the prostaglandin-E-receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem. 1993; 217:313-318.
6. Hohlfeld T, Zucker TP, Meyer J, Schror K. Expression, function, and regulation of E-type prostaglandin receptors (EP3) in the nonischemic and ischemic pig heart. Circ Res. 1997;81:765-773.
7. Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC. Dissimilar effects of prostacyclin, prostaglandin E1, and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res. 1981; 49:685-700.
8. Schror K, Thiemermann C, Ney P. Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation. Naunvn Schmiedebergs Arch Pharmacol. 1988;338:268-274.
9. Simpson PJ, Mickelson J, Fantone JC, Gallagher KP, Lucchesi BR. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. J Pharmacol Exp Ther. 1988;244:619-624.
10. Hide EJ, Ney P, Piper J, Thiemermann C, Vane JR. Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 1995;116:2435-2440.
11. Lucchesi BR, Mullane KM. Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol. 1986;26:201-224.
12. Schror K. Eicosanoids and myocardial ischaemia. Basic Res Cardiol. 1987;82:235-243.
13. Hide EJ, Thiemermann C. Sulprostone-induced reduction of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 1996;118:1409-1414.
14. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46: 205-229.
15. Hohlfeld T. Regulation of prostaglandin receptors in myocardial ischemia. Agents Actions Suppl. 1995;45:33-37.
16. Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, Narumiya S. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem. 1992;267:6463-6466.
17. Thiemermann C, Thomas GR, Vane JR. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischaemia and reperfusion. Br J Pharmacol. 1989;97:401-408.
18. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s? Circulation. 1993;88:750-763.
19. Hohlfeld T, Meyer J, Schror K. Myocardial EP3 receptors are externalized in ischemic porcine hearts and mediate reduction of ischemic myocardial injury. Naunyn Schmiedebergs Arch Pharmacol. 1998; 357:R103. Abstract.
20. Downey JM, Cohen MV. Signal transduction in ischemic preconditioning. Z Kardiol. 1995;84:77-86.
21. Millar CG, Baxter GF, Thiemermann C. Protection of the myocardium by ischaemic preconditioning: mechanisms and therapeutic implications. Pharmacol Ther. 1996;69:143-151.
22. Speechly-Dick ME, Mocanu MM. Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 1994;75:586-590.
23. Kaye AD, Nossaman BD, Ibrahim IN, Feng CJ, Kadowitz PJ. Influence of protein kinase C inhibitors on vasoconstrictor responses in the pulmonary vascular bed of cat and rat. Am J Physiol. 1995;268:L532-L538.
24. Kozak W, Klir JJ, Conn CA, Kluger MJ. Attenuation of lipopolysaccharide fever in rats by protein kinase C inhibitors. Am J Physiol. 1997;273: R873-R879.
25. Yoshida K, Kawamura S, Mizukami Y, Kitakaze M. Implication of protein kinase C-α, δ, and ε isoforms in ischemic preconditioning in perfused rat hearts. J Biochem (Tokyo). 1997;122:506-511.
26. Robert A. On the mechanism of cytoprotection by prostaglandins. Ann Clin Res. 1984;16:335-338.